BASF inorganic specialties divestiture creates new business named Callery
Current product portfolio includes a range of specialty alkoxide bases and borane derivatives.
BASF has created Callery as the new stand-alone entity born from BASF's divestment of its inorganic specialties business. The divestiture was facilitated by Edgewater Capital in combination with the Callery management team. Callery is a global leader in highly reactive chemistries, supplying products to the pharmaceutical, fine, and specialty chemical arenas.
Callery's current product portfolio includes a range of specialty alkoxide bases and borane derivatives, as well as a variety of custom products based on the company's core competency in the handling of highly reactive compounds. Callery's world-class facility includes R&D labs, pilot plant, large-scale production facilities and all knowledge associated with existing and developmental products.
Bob Girton, member of Callery's Board of Directors, said: "We are grateful for all of the hard work by the transition team over the last several months for helping us carve out the Callery business from BASF with minimal impact on our customers. We are excited to join them in taking Callery to its next level of success and build on the business' commitment to environmental health and safety, a high level of product quality, and industry leading reagent and organometallic technology."
The company's products have enabled some of the world's most impressive innovations, including billion-dollar blockbuster drugs, agro chemicals, and other high performance products from electronics to polymer applications.
Soon, Callery will be announcing its new management team to lead the company on its growth path in the coming years. The company is committed to the continued delivery of innovative products that enable customer success.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance